Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 234-842-7 | CAS number: 12036-22-5
All animals survived till the end of the study.
- Step 1: There were no significant differences in the mean body weights between the animals of the test substance group and those of the control group on Days 0 and 25.
- Step 2: There were no significant differences in the mean body weights between the test substance group and the control group on Day 0. On Day 25 the mean body weight of the test substance group animals was slightly, but statistically, higher than that of the control animals. This was of no biological significance and was regarded as a random event.
Immediately after the beginning of all epicutaneous exposures (inductions, challenge) the motor activities of all animals were increased. This is due to the dressings which restrict the freedom of movement. Soon afterwards the behaviour was regular again. Except of the observations described above no abnormal behaviour or clinical signs were detected during the experiment in the animals.
Skin reactions after the intradermal FCA administration
Cranial and caudal injection sites: Local irritations were observed in all animals beginning on the day after the injections. The irritations started with local erythema, which became more severe and led to ulcerations. Lesions did not heal until the end of the study. These local alterations are known effects of Freund's adjuvant.
Skin reactions after the first and the second induction exposure
All animals of both groups had severe erythema and oedema in the interscapula region which were attributed to the effects of the adjuvant.
No skin sensitisation data of sufficient quality are available for tungsten dioxide (target substance). However, skin sensitiationtoxicity data are available for tungsten trioxide (source substance), which are used for read-across. Due to similar water solubility, in vitro bioaccessibility in synthetic alveolar, lysosomal, and interstitial fluids simulating inhalation exposure, and available toxicity data for the target and source substances, the resulting toxicity potential would also be expected to be similar, so read-across is appropriate between these substances. In addition, read-across is appropriate for this endpoint because the classification and labeling is the same for the source and target substances, the PBT/vPvB profile is the same, and the dose descriptors are, or are expected to be, sufficiently similar. For more details, refer to the read-across category approach included in the Category section of this IUCLID submission and/or as Annex 3 in the CSR.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Close Do not show this message again